Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance of remission with secukinumab in non-radiographic axial spondyloarthritis
2023-509320-17-00Phase 4Authorised
- Sponsor
- Novartis
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 4, randomised, double-blind trial in non-radiographic axial spondyloarthritis (nr-axSpA) comparing Secukinumab continuation with Placebo withdrawal with possible retreatment (2 arms). Primary endpoint: Proportion of participants remaining flare-free at Week 120. Planned start May 2024; status: authorised.
02
Drugs
secukinumab
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on 2023-509320-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509320-17-00.